EP300/CREBBP inhibitor
US11274100B2 · kind B2 · utility
0Cited by
0References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2018 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | Jun 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.